Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of INM004 added to standard of care in pediatric STEC-associated hemolytic uremic syndrome
NL-OMON59741Phase 3Not yet recruiting
- Sponsor
- Chemo
- Start
- Oct 2024
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of equine immunoglobulin F(ab')2 fragments targeting Shiga toxin in hemolytic uremic syndrome (HUS) and Shiga-toxin producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS), sponsored by Chemo. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
equine immunoglobulin F(ab')2 fragments targeting Shiga toxin
03
Conditions
hemolytic uremic syndrome (HUS)Shiga-toxin producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS)
Beyond the preview
Go deeper on NL-OMON59741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59741.